IL-1 receptors mediate persistent, but not acute, airway hyperreactivity to ozone in guinea pigs.
Kirsten C Verhein, David B Jacoby, Allison D Fryer
文献索引:Am. J. Respir. Cell. Mol. Biol. 39(6) , 730-8, (2008)
全文:HTML全文
摘要
Ozone exposure in the lab and environment causes airway hyperreactivity lasting at least 3 days in humans and animals. In guinea pigs 1 day after ozone exposure, airway hyperreactivity is mediated by eosinophils that block neuronal M(2) muscarinic receptor function, thus increasing acetylcholine release from airway parasympathetic nerves. However, mechanisms of ozone-induced airway hyperreactivity change over time, so that depleting eosinophils 3 days after ozone makes airway hyperreactivity worse rather than better. Ozone exposure increases IL-1beta in bone marrow, which may contribute to acute and chronic airway hyperreactivity. To test whether IL-1beta mediates ozone-induced airway hyperreactivity 1 and 3 days after ozone exposure, guinea pigs were pretreated with an IL-1 receptor antagonist (anakinra, 30 mg/kg, intraperitoneally) 30 minutes before exposure to filtered air or to ozone (2 ppm, 4 h). One or three days after exposure, airway reactivity was measured in anesthetized guinea pigs. The IL-1 receptor antagonist prevented ozone-induced airway hyperreactivity 3 days, but not 1 day, after ozone exposure. Ozone-induced airway hyperreactivity was vagally mediated, since bronchoconstriction induced by intravenous acetylcholine was not changed by ozone. The IL-1 receptor antagonist selectively prevented ozone-induced reduction of eosinophils around nerves and prevented ozone-induced deposition of extracellular eosinophil major basic protein in airways. These data demonstrate that IL-1 mediates ozone-induced airway hyperreactivity at 3 days, but not 1 day, after ozone exposure. Furthermore, preventing hyperreactivity was accompanied by decreased eosinophil major basic protein deposition within the lung, suggesting that IL-1 affects eosinophil activation 3 days after ozone exposure.
相关化合物
相关文献:
2015-03-01
[J. Pharmacol. Exp. Ther. 352(3) , 462-70, (2015)]
2014-10-30
[Oncogene 33(44) , 5193-200, (2014)]
2014-09-01
[Arch. Toxicol. 88(9) , 1695-709, (2014)]
2015-11-15
[Life Sci. 141 , 44-53, (2015)]
2015-02-17
[Toxicol. Lett. 233(1) , 8-15, (2015)]